Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06878144 · ClinicalTrials.gov registry record
Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Not yet
- Registry status
- 300
- Enrollment target
NCT06878144: Clinical Trial study, sponsored by M.D. Anderson Cancer Center.
NCT06878144 is a clinical trial that has not yet begun recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06878144 has not yet begun recruiting, sponsored by M.D. Anderson Cancer Center.
- NOT YET RECRUITING
- Registry status
- 300 participants
- Enrollment target
Study Summary
To collect data and samples from participants with cancer who also have invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection.
Interventions
- BEHAVIORAL Mucormycosis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2032-12-31 |
What is known before NCT06878144 opens enrollment
NCT06878144 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Mucormycosis is the first listed.
NCT06878144 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06878144 about?
NCT06878144 is a clinical study titled "Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project". To collect data and samples from participants with cancer who also have invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection.
What is the current status of trial NCT06878144?
This trial is currently not yet recruiting. The enrollment target is 300 participants. The study started on 2025-09-30. Estimated completion is 2032-12-31.
What interventions are being tested in trial NCT06878144?
The interventions under investigation include: Mucormycosis (BEHAVIORAL).
Who is sponsoring clinical trial NCT06878144?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI